Andrew R Raubitschek

Title: Andrew R Raubitschek: Innovator in Monoclonal Antibody Development

Introduction

Andrew R Raubitschek is a notable inventor based in Palo Alto, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents, his work has had a lasting impact on medical research and applications.

Latest Patents

Raubitschek's latest patents include groundbreaking innovations. One of his patents describes a human lymphoblastoid cell line and hybridomas derived therefrom. This patent details a 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2, designated LTR228, which fuses efficiently with human cells. Additionally, he has developed human monoclonal antibodies against group A red blood cells, which are useful as ABO typing reagents. The exemplified antibody is an IgM produced by hybrid cell lines S-H22 and HHA1.

Career Highlights

Throughout his career, Raubitschek has worked with prominent organizations such as Cetus Corporation and Leland Stanford Junior University. His work in these institutions has allowed him to advance his research and contribute to significant scientific discoveries.

Collaborations

Raubitschek has collaborated with esteemed colleagues, including James W Larrick and Kenneth E Truitt. These partnerships have further enriched his research and innovation in the field of biotechnology.

Conclusion

Andrew R Raubitschek's contributions to the development of monoclonal antibodies and his innovative patents have established him as a key figure in biotechnology. His work continues to influence the medical field and enhance our understanding of immunology.